30th Jan 2019 11:45
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or the "Company")
Schedule 2(g) Disclosure
Advanced Oncotherapy (AIM: AVO), the developer of a next-generation proton therapy system for cancer treatment, announces the following updates to disclosure in relation to Gabriel Urwitz, Non-Executive Director of the Company, pursuant to AIM Rule 17 and Schedule 2(g)(iii) to (viii) of the AIM Rules.
Gabriel Urwitz was a director of Oidun AB from 28 December 2007 to 24 September 2015. The company entered into liquidation on 15 September 2015 and bankruptcy proceedings were filed on 29 September 2015.
For further information, please contact:
Advanced Oncotherapy Plc | www.avoplc.com |
Dr. Michael Sinclair, Executive Chairman | Tel: +44 20 3617 8728 |
Nicolas Serandour, CEO | |
Stockdale Securities (Nomad & Joint Broker) | |
Antonio Bossi / David Coaten | Tel: +44 20 7601 6100 |
Stifel Nicolaus Europe (Joint Broker) | |
Jonathan Senior | Tel: +44 20 7710 7600 |
Walbrook PR (Financial PR & IR) | Tel: +44 20 7933 8780 or [email protected] |
Paul McManus / Anna Dunphy | Mob: +44 7980 541 893 / Mob: +44 7876 741 001 |
About Advanced Oncotherapy Plc www.avoplc.com
Advanced Oncotherapy is a provider of particle therapy in the treatment of cancer, which harnesses the very best in modern technology. Advanced Oncotherapy's R&D team, ADAM, in Geneva, focuses on the development of a proprietary proton accelerator - LIGHT (Linac Image Guided Hadron Technology). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a compact and truly modular unit, offering significant cost advantages. LIGHT also delivers proton beams in a way that facilitates greater precision and electronic control, which are not achievable with currently available alternative technologies.
Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology, offering better health outcomes and lower treatment related side effects.
Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton or particle therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of cutting edge, cost-effective systems for particle therapy.
Related Shares:
AVO.L